Quantcast

Latest FDA Stories

2014-07-07 23:06:26

On July 1, the FDA published that 6 lots of Coumadin (Warfarin Sodium) for Injection, 5 mg single-use vials, by Bristol-Myers Squibb, are recalled due to the presence of visible particulate matter. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) July 07, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on...

2014-07-07 16:23:47

First Recombinant Treatment Approved in US for Patients With GT With Refractoriness to Platelet Transfusions, With or Without Antibodies to Platelets PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven(®) RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative management in patients with Glanzmann's Thrombasthenia (GT) with refractoriness to...

2014-07-07 12:29:12

- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) EAST HANOVER, N.J., July 7, 2014 /PRNewswire/ -- Novartis announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic...

2014-07-07 12:28:59

Engineered Cells Known As CTL019 Are the First Therapy of Their Kind to Obtain Designation PHILADELPHIA, July 7, 2014 /PRNewswire/ -- A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). The investigational therapy, known as CTL019, is the first personalized cellular therapy for the...

2014-07-07 08:27:11

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, July 7, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), StemCells, Inc. (NASDAQ: STEM) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN). Private wealth members receive these notes ahead of publication. To reserve...

2014-07-04 23:04:02

On June 30, the FDA warned not to use injectable vitamin drug products labeled “Sunshine Labs” and distributed by Medical Supply Liquidators because they are not FDA approved. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) July 04, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Injectable Vitamin...

2014-07-03 23:09:54

On June 26, the FDA informed that prescription oral viscous lidocaine 2% solution should not be used to treat infants and children with teething pain. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. (PRWEB) July 03, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Lidocaine Viscous. The FDA issued a safety...

2014-07-03 23:02:45

Zoll, Kranz & Borgess, LLC currently represents clients with injuries allegedly caused by testosterone therapy. Toledo, OH (PRWEB) July 03, 2014 The FDA is now requiring all testosterone replacement therapy products to have the general warning that these drugs may cause blood clots in the veins (Venous Thromboembolism (VTE)). Currently, the VTE warning is directly linked to polycythemia, which is when there is an increase in the number of red blood cells. Announced by the FDA June...

2014-07-02 23:09:29

On June 25, the FDA warned that specific over-the-counter topical acne products can cause rare but serious, potentially life-threatening, allergic reactions. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) July 02, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on over-the-counter topical acne products....

2014-07-01 23:12:54

On June 24, the FDA communicated that there is no clear evidence of increased cardiovascular risks associated with use of Olmesartan in diabetic patients. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) July 01, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Olmesartan. The FDA issued...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related